For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
259
views
23
references
 Top references
cited by
119
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      603
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: not found

      Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses.

      Author(s): 1 , 1 , 2 , 3 , 4 , 4 , 1 , 2 , 5 , 5 , 6 , 6 , 6 , 7 , 7 , 7 , 8 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 15 , 16 , 17 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 3 , 26 , 2 , 5 , 26 , 27
      Publication date (Electronic):
      Journal: Annals of neurology

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Neuromyelitis optica (NMO) attacks often are severe, are difficult to treat, and leave residual deficits. Here, we analyzed the frequency, sequence, and efficacy of therapies used for NMO attacks.

          Related collections

          Most cited references23

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients

          Sven Jarius, Klemens Ruprecht, Brigitte Wildemann … (2012)
          Background The diagnostic and pathophysiological relevance of antibodies to aquaporin-4 (AQP4-Ab) in patients with neuromyelitis optica spectrum disorders (NMOSD) has been intensively studied. However, little is known so far about the clinical impact of AQP4-Ab seropositivity. Objective To analyse systematically the clinical and paraclinical features associated with NMO spectrum disorders in Caucasians in a stratified fashion according to the patients' AQP4-Ab serostatus. Methods Retrospective study of 175 Caucasian patients (AQP4-Ab positive in 78.3%). Results Seropositive patients were found to be predominantly female (p 1 myelitis attacks in the first year were identified as possible predictors of a worse outcome. Conclusion This study provides an overview of the clinical and paraclinical features of NMOSD in Caucasians and demonstrates a number of distinct disease characteristics in seropositive and seronegative patients.
          Article 0 comments Cited 259 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            EFNS guidelines on diagnosis and management of neuromyelitis optica.

            Z Illes, Kristina Sørensen, Wolfgang Hemmer … (2010)
            Neuromyelitis optica (NMO) or Devic's disease is a rare inflammatory and demyelinating autoimmune disorder of the central nervous system (CNS) characterized by recurrent attacks of optic neuritis (ON) and longitudinally extensive transverse myelitis (LETM), which is distinct from multiple sclerosis (MS). The guidelines are designed to provide guidance for best clinical practice based on the current state of clinical and scientific knowledge. Evidence for this guideline was collected by searches for original articles, case reports and meta-analyses in the MEDLINE and Cochrane databases. In addition, clinical practice guidelines of professional neurological and rheumatological organizations were studied. Different diagnostic criteria for NMO diagnosis [Wingerchuk et al. Revised NMO criteria, 2006 and Miller et al. National Multiple Sclerosis Society (NMSS) task force criteria, 2008] and features potentially indicative of NMO facilitate the diagnosis. In addition, guidance for the work-up and diagnosis of spatially limited NMO spectrum disorders is provided by the task force. Due to lack of studies fulfilling requirement for the highest levels of evidence, the task force suggests concepts for treatment of acute exacerbations and attack prevention based on expert opinion. Studies on diagnosis and management of NMO fulfilling requirements for the highest levels of evidence (class I-III rating) are limited, and diagnostic and therapeutic concepts based on expert opinion and consensus of the task force members were assembled for this guideline.
            Article 0 comments Cited 113 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Plasma exchange for severe attacks of CNS demyelination: predictors of response.

              A. Morelos Pineda, Marta García-Clemente, C J McClelland … (2002)
              The authors reviewed 59 consecutive patients treated with plasma exchange (PE) for acute, severe attacks of CNS demyelination at Mayo Clinic from January 1984 through June 2000. Most patients had relapsing-remitting MS (n = 22, 37.3%), neuromyelitis optica (NMO) (n = 10, 16.9%), and acute disseminated encephalomyelitis (n = 10, 16.9%). PE was followed by moderate or marked functional improvement in 44.1% of treated patients. Male sex (p = 0.021), preserved reflexes (p = 0.019), and early initiation of treatment (p = 0.009) were associated with moderate or marked improvement. Successfully treated patients improved rapidly following PE, and improvement was sustained.
              Article 0 comments Cited 100 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (iso-abbrev): Ann. Neurol.
                Title: Annals of neurology
                ISSN (Electronic): 1531-8249
                ISSN (Print): 0364-5134
                Publication date (Electronic): Feb 2016
                Volume: 79
                Issue: 2
                Affiliations
                [1 ] Department of Neurology, St. Josef-Hospital, Ruhr University Bochum, Bochum.
                [2 ] NeuroCure Clinical Research Center and Experimental and Clinical Research Center, Charité University Medicine, and Max Delbrueck Center for Molecular Medicine, Berlin.
                [3 ] Department of Neurology, Asklepios Clinic Teupitz, Teupitz.
                [4 ] Clinical Research Organisation Sostana and Charité University Medicine, Berlin.
                [5 ] Department of Neurology and Clinical and Experimental Multiple Sclerosis Research Center, Charité University Medicine, Berlin.
                [6 ] Institute of Clinical Neuroimmunology, Medical Campus Grosshadern, Ludwig Maximilians University, Munich.
                [7 ] Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf.
                [8 ] Department of Neurology, University Hospital Würzburg, Würzburg.
                [9 ] Department of Neurology, Technical University of Munich, Munich.
                [10 ] Department of Neurology, Technical University of Munich and Munich Cluster for Systems Neurology, Munich.
                [11 ] Department of Neurology, University Hospital Regensburg, Regensburg.
                [12 ] Institute for Neuroimmunology and MS and Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg.
                [13 ] Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg.
                [14 ] Clinical Neuroimmunology and Neurochemistry, Department of Neurology, Hannover Medical School, Hannover.
                [15 ] Department of Neurology, University of Ulm, Ulm.
                [16 ] Department of Neurology, Goethe University Frankfurt, Frankfurt.
                [17 ] Department of Neurology and Stroke and Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen.
                [18 ] Department of Neurology, Friedrich Alexander University Erlangen-Nuremberg, Erlangen.
                [19 ] Hans Berger Department of Neurology, Jena University Hospital, Jena.
                [20 ] Department of Neurology, University of Münster, Münster.
                [21 ] Department of Neurology, University of Leipzig, Leipzig.
                [22 ] Department of Neurology, Bayreuth Medical Center, Bayreuth.
                [23 ] Department of Neurology, SRH Hospital Sigmaringen, Sigmaringen.
                [24 ] Department of Neurology, University of Rostock, Rostock.
                [25 ] Department of Neurology, HELIOS Hanse Hospital Stralsund, Stralsund.
                [26 ] Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg.
                [27 ] Department of Neurology, Hannover Medical School, Hannover, Germany.
                Article
                DOI: 10.1002/ana.24554
                PubMed ID: 26537743
                SO-VID: eceec033-c4a1-443c-af4a-6d2eeac0b445
                Copyright © © 2015 American Neurological Association.
                History

                Data availability:

                Comments

                Comment on this article

                scite_

                Similar content603

                See all similar

                Cited by118

                See all cited by

                Most referenced authors514

                See all reference authors